Tag Archives: Edward White

H.C. Wainwright Believes TRACON Pharmaceuticals (NASDAQ: TCON) Won’t Stop Here

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TRACON Pharmaceuticals (TCON – Research Report), with a price target of $7.00. The company’s shares closed last Monday at $5.66, close to its 52-week high

H.C. Wainwright Maintains a Buy Rating on Clovis Oncology (CLVS)

H.C. Wainwright analyst Edward White maintained a Buy rating on Clovis Oncology (CLVS – Research Report) today and set a price target of $23.00. The company’s shares closed last Friday at $6.97. According to TipRanks.com, White is a 5-star analyst

Analysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (NASDAQ: TCON), Shockwave Medical (NASDAQ: SWAV) and Seres Therapeutics (NASDAQ: MCRB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TRACON Pharmaceuticals (TCON – Research Report), Shockwave Medical (SWAV – Research Report) and Seres Therapeutics (MCRB – Research Report). TRACON Pharmaceuticals (TCON) H.C. Wainwright analyst

Aeglea Biotherapeutics (AGLE) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Edward White maintained a Buy rating on Aeglea Biotherapeutics (AGLE – Research Report) today and set a price target of $17.00. The company’s shares closed last Tuesday at $7.65. According to TipRanks.com, White is a 5-star analyst

Analysts Offer Insights on Healthcare Companies: Allena Pharmaceuticals (NASDAQ: ALNA) and Beyondspring (NASDAQ: BYSI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allena Pharmaceuticals (ALNA – Research Report) and Beyondspring (BYSI – Research Report) with bullish sentiments. Allena Pharmaceuticals (ALNA) In a report issued

Analysts’ Top Healthcare Picks: Dynavax (DVAX), Galmed Pharmaceuticals (GLMD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX – Research Report), Galmed Pharmaceuticals (GLMD – Research Report) and Sarepta Therapeutics (SRPT – Research Report) with bullish sentiments. Dynavax